CY1121472T1 - Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη - Google Patents

Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη

Info

Publication number
CY1121472T1
CY1121472T1 CY20181101244T CY181101244T CY1121472T1 CY 1121472 T1 CY1121472 T1 CY 1121472T1 CY 20181101244 T CY20181101244 T CY 20181101244T CY 181101244 T CY181101244 T CY 181101244T CY 1121472 T1 CY1121472 T1 CY 1121472T1
Authority
CY
Cyprus
Prior art keywords
cholesterol
system containing
delivery system
containing phospholipid
ophthalmic delivery
Prior art date
Application number
CY20181101244T
Other languages
English (en)
Inventor
Sheue-Fang Shih
Po-Chun Chang
Yun-Long Tseng
Luke S.S. Guo
Keelung Hong
Original Assignee
Taiwan Liposome Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Company, Ltd. filed Critical Taiwan Liposome Company, Ltd.
Publication of CY1121472T1 publication Critical patent/CY1121472T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Ένα σύστημα οφθαλμικής αποδέσμευσης φαρμάκου που περιέχει φωσφολιπίδιο και χοληστερόλη για την παράταση της διάρκειας ζωής του φαρμάκου στους οφθαλμούς.
CY20181101244T 2009-08-10 2018-11-23 Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη CY1121472T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/538,435 US8956600B2 (en) 2009-08-10 2009-08-10 Ophthalmic drug delivery system containing phospholipid and cholesterol
PCT/US2010/022487 WO2011019410A1 (en) 2009-08-10 2010-01-29 Ophthalmic drug delivery system containing phospholipid and cholesterol
EP10808467.4A EP2464343B1 (en) 2009-08-10 2010-01-29 Ophthalmic drug delivery system containing phospholipid and cholesterol

Publications (1)

Publication Number Publication Date
CY1121472T1 true CY1121472T1 (el) 2020-05-29

Family

ID=43534994

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181101245T CY1121467T1 (el) 2009-08-10 2018-11-23 Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη
CY20181101244T CY1121472T1 (el) 2009-08-10 2018-11-23 Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181101245T CY1121467T1 (el) 2009-08-10 2018-11-23 Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη

Country Status (18)

Country Link
US (4) US8956600B2 (el)
EP (3) EP2464343B1 (el)
JP (2) JP5816623B2 (el)
KR (2) KR101787775B1 (el)
CN (2) CN102573800B (el)
AU (1) AU2010282983B2 (el)
BR (1) BR112012002981B8 (el)
CA (1) CA2769929C (el)
CY (2) CY1121467T1 (el)
DK (2) DK2464343T3 (el)
ES (2) ES2699178T3 (el)
HK (2) HK1172564A1 (el)
NZ (2) NZ623450A (el)
PT (2) PT2464343T (el)
RU (1) RU2572213C2 (el)
TW (1) TWI515008B (el)
WO (1) WO2011019410A1 (el)
ZA (1) ZA201201034B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
SG11201404230QA (en) * 2012-01-31 2014-10-30 Santen Pharmaceutical Co Ltd Non-aqueous liquid composition
CA2862055C (en) * 2012-02-10 2020-03-10 Taiwan Liposome Company, Ltd. Pharmaceutical compositions to reduce complications of ocular steroid
JP6044920B2 (ja) * 2012-03-27 2016-12-14 国立研究開発法人農業・食品産業技術総合研究機構 酸化ｌｄｌ受容体に作用するリポソーム
WO2014008469A2 (en) * 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Methods of treating arthritis
CA2878946A1 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
US11458199B2 (en) 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
HUE058912T2 (hu) * 2012-08-21 2022-09-28 Opko Pharmaceuticals Llc Liposzóma készítmények
EA022183B1 (ru) * 2012-12-24 2015-11-30 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы цитохрома с
US10342846B2 (en) 2013-02-04 2019-07-09 University Of Notre Dame Du Lac Nanoparticle drug delivery systems
WO2014196621A1 (ja) * 2013-06-07 2014-12-11 Ｋｔｎバイオテック株式会社 抗癌剤
US9895312B2 (en) * 2014-04-08 2018-02-20 Pablo E. Vivas-Mejia Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
CA3010056A1 (en) * 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6697541B2 (ja) * 2016-01-07 2020-05-20 ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ 膀胱癌処置のための処方物
JP2019515925A (ja) * 2016-04-29 2019-06-13 エンセラドゥス ファーマセウティカルス べー．フェー． 炎症性病変又は領域に局所注射するためのリポソーム化コルチコステロイド
IL264842B (en) * 2016-08-18 2022-08-01 Troy Bremer Delivery of urea to macular and retinal cells using liposome constructs
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN110743035A (zh) * 2019-11-06 2020-02-04 广西大学 一种智能抗菌的水凝胶的制备方法及其应用
GB201917487D0 (en) * 2019-11-29 2020-01-15 Oxular Ltd Methods for the treatment of retinoblastoma
EP4301343A1 (en) 2021-03-05 2024-01-10 TLC Biopharmaceuticals, Inc. Pharmaceutical compositions with reduced side effect and methods of using the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550960A (en) * 1895-12-10 Island
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
ES2090966T3 (es) 1992-02-12 1996-10-16 Janssen Cilag S P A Formulaciones liposomicas con piroxicam.
TR199701683A2 (xx) 1997-12-18 2001-06-21 Eldem Türkan Oküler ve parenteral polimer kaplı lipozomal ilaç taşıyıcı sistemler.
NZ514918A (en) * 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
DE10032627A1 (de) 2000-07-07 2002-01-17 Km Europa Metal Ag Verwendung einer Kupfer-Nickel-Legierung
JP2005525992A (ja) 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US20040224010A1 (en) 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
WO2004047800A2 (en) 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
ES2406764T3 (es) * 2006-06-16 2013-06-10 Regeneron Pharmaceuticals, Inc. Formulaciones que comprenden antagonistas de VEGF para administración intravítrea
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Also Published As

Publication number Publication date
EP2813229B1 (en) 2018-08-29
AU2010282983B2 (en) 2016-09-22
PT2464343T (pt) 2018-12-05
US20110033468A1 (en) 2011-02-10
CA2769929C (en) 2018-01-02
BR112012002981B1 (pt) 2020-12-01
ES2699249T3 (es) 2019-02-08
KR101921852B1 (ko) 2018-11-23
EP2464343A4 (en) 2013-01-23
CA2769929A1 (en) 2011-02-17
DK2464343T3 (da) 2019-01-02
CN105148278B (zh) 2019-11-05
CY1121467T1 (el) 2020-05-29
BR112012002981B8 (pt) 2021-05-25
AU2010282983A1 (en) 2012-03-01
CN102573800A (zh) 2012-07-11
JP2015164961A (ja) 2015-09-17
NZ623450A (en) 2015-06-26
KR20170107106A (ko) 2017-09-22
BR112012002981A2 (pt) 2016-04-19
EP3275445A1 (en) 2018-01-31
KR20120083316A (ko) 2012-07-25
NZ598656A (en) 2014-04-30
US20180169248A1 (en) 2018-06-21
HK1172564A1 (zh) 2013-04-26
EP2464343B1 (en) 2018-08-29
JP5816623B2 (ja) 2015-11-18
JP2013501786A (ja) 2013-01-17
US10660960B2 (en) 2020-05-26
ZA201201034B (en) 2015-06-24
RU2012108888A (ru) 2013-09-20
KR101787775B1 (ko) 2017-10-18
CN105148278A (zh) 2015-12-16
US9987360B2 (en) 2018-06-05
US20150147320A1 (en) 2015-05-28
CN102573800B (zh) 2015-09-30
WO2011019410A1 (en) 2011-02-17
US20200289652A1 (en) 2020-09-17
HK1214946A1 (zh) 2016-08-12
PT2813229T (pt) 2018-11-30
US8956600B2 (en) 2015-02-17
ES2699178T3 (es) 2019-02-07
EP2464343A1 (en) 2012-06-20
TW201105350A (en) 2011-02-16
RU2572213C2 (ru) 2015-12-27
DK2813229T3 (en) 2018-12-17
JP6243874B2 (ja) 2017-12-06
TWI515008B (zh) 2016-01-01
US11771766B2 (en) 2023-10-03
EP2813229A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
CY1121467T1 (el) Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
EP2600834A4 (en) COLLAGEN IMPLANTS FOR THE SUSTAINABLE DELIVERY OF MEDICAMENTS
PH12015500115A1 (en) Glucagon analogues
PL2262476T3 (pl) Dostarczanie leku do przedniego i tylnego odcinka oka z użyciem kropli do oczu
ZA201209630B (en) Photodynamic bone stabilization and drug delivery systems
MX2014010913A (es) Composicion farmaceutica que comprende farmaco empagliflozina y antiobesidad.
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
DK2281576T3 (da) Aktiv målsøgende polymermicelle med deri indkapslet medikament samt medicinsk sammensætning
MX366230B (es) Composiciones multipolimericas para liberación transdermica de farmaco.
WO2009129387A3 (en) Cationic lipids and uses thereof
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
IN2014MN01886A (el)
IL227352A0 (en) A system for ocular administration of a drug
GB201204632D0 (en) Delivery system
WO2012024634A3 (en) Environmentally-responsive nanocomposites and methods of their use
AU330684S (en) Medical dispensing device
AU339334S (en) Wheelchair chassis
EA201491991A1 (ru) Новая система высвобождения гидрофобных белков
UY34667A (es) ?método y dispositivo para el tratamiento de trastornos del colesterol en la sangre?.
UA75204U (uk) Спазмолітичний та седативний лікарський засіб у формі м'яких желатинових капсул
UA69854U (ru) Антисептическое средство для санации слизистых оболочек
UA52520U (ru) Способ лечения нарушений функционального состояния кишечника у новорожденных и детей младенческого возраста